WP
CRSP icon

Woodline Partners’s CRISPR Therapeutics CRSP Stock Holding History

Woodline Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-143,575
Closed -$9.31M – 1045
2025
Q3 		$9.31M Sell
143,575
-5,692
-4% -$327K 0.04% 454
2025
Q2 		$7.26M Buy
149,267
+12,784
+9% +$495K 0.04% 490
2025
Q1 		$4.64M Buy
136,483
+34,883
+34% +$1.48M 0.03% 526
2024
Q4 		$4M Buy
101,600
+1,600
+2% +$75.6K 0.03% 528
2024
Q3 		$4.7M Sell
100,000
-26,839
-21% -$1.36M 0.04% 394
2024
Q2 		$6.85M Sell
126,839
-36,738
-22% -$2.13M 0.07% 303
2024
Q1 		$11.1M Buy
163,577
+113,544
+227% +$8.13M 0.1% 246
2023
Q4 		$3.13M Sell
50,033
-50,379
-50% -$2.79M 0.03% 356
2023
Q3 		$4.56M Buy
100,412
+50,412
+101% +$2.6M 0.05% 322
2023
Q2 		$2.81M Buy
+50,000
New +$2.84M 0.03% 383
2022
Q2 		– Sell
-189,126
Closed -$11.9M – 814
2022
Q1 		$11.9M Buy
189,126
+179,759
+1,919% +$11.3M 0.19% 154
2021
Q4 		$710K Buy
+9,367
New +$818K 0.01% 536

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GP
GSK plc London $599M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners's CRSP Position: Q4 2025 in Review

Woodline Partners sold out of CRISPR Therapeutics (CRSP) in Q4 2025, closing a stake of 143,575 shares — an estimated $9.31M sold.

Woodline Partners first reported a position in CRSP in Q4 2021 and held it in 12 quarters. The position peaked at $11.9M in Q1 2022. 479 funds tracked by Wall St. Rank hold CRSP as of Q4 2025.

  • Woodline Partners reported no remaining CRISPR Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Woodline Partners sold 143,575 CRISPR Therapeutics shares in Q4 2025, an estimated $9.31M.
  • Woodline Partners first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 12 quarters.
  • Woodline Partners's CRISPR Therapeutics position peaked at $11.9M in Q1 2022.
  • 479 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2025.

Based on Woodline Partners's 13F filing for Q4 2025, filed 17 Feb 2026.